Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:00 pm Sale |
2023-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-4,215,864 (Position Closed) |
Filing History |
| 2023-05-05 4:37 pm Purchase |
2023-05-03 | 13G | TCR2 Therapeutics Inc. TCRR |
TANG CAPITAL PARTNERS LP | 4,215,864 10.700% |
1,476,917 (+53.92%) |
Filing History |
| 2023-02-14 4:00 pm Sale |
2022-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
TANG CAPITAL PARTNERS LP | 2,738,947 7.100% |
-61,053 (-2.18%) |
Filing History |
| 2023-02-08 5:51 pm Sale |
2022-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
K2 PRINCIPAL FUND L.P. | 0 0.000% |
-1,950,628 (Position Closed) |
Filing History |
| 2022-08-31 6:13 pm Purchase |
2022-08-26 | 13G | TCR2 Therapeutics Inc. TCRR |
K2 PRINCIPAL FUND L.P. | 1,950,628 5.050% |
1,950,628 (New Position) |
Filing History |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | TCR2 Therapeutics Inc. TCRR |
BLACKROCK INC BLK |
1,037,694 2.700% |
-1,364,051 (-56.79%) |
Filing History |
| 2022-03-04 4:00 pm Purchase |
2022-02-22 | 13G | TCR2 Therapeutics Inc. TCRR |
TANG CAPITAL PARTNERS LP | 2,800,000 7.300% |
2,800,000 (New Position) |
Filing History |
| 2022-02-14 5:07 pm Sale |
2021-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
Redmile Group LLC | 1,346,058 3.500% |
-1,486,830 (-52.48%) |
Filing History |
| 2022-02-03 4:41 pm Sale |
2021-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
BLACKROCK INC BLK |
2,401,745 6.300% |
-201,794 (-7.75%) |
Filing History |
| 2021-11-10 08:51 am Sale |
2021-10-29 | 13G | TCR2 Therapeutics Inc. TCRR |
WELLINGTON MANAGEMENT CO LLP | 1,131,347 2.960% |
-2,622,017 (-69.86%) |
Filing History |
| 2021-02-16 4:09 pm Purchase |
2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
Redmile Group LLC | 2,832,888 8.500% |
1,033,700 (+57.45%) |
Filing History |
| 2021-02-16 1:29 pm Sale |
2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
ArrowMark Colorado Holdings LLC | 1,167,220 3.500% |
-102,546 (-8.08%) |
Filing History |
| 2021-02-09 06:17 am Sale |
2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
Upnorth Investment Ltd | 1,281,392 3.800% |
-856,027 (-40.05%) |
Filing History |
| 2021-02-02 2:56 pm Purchase |
2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
BLACKROCK INC BLK |
2,603,539 7.800% |
2,603,539 (New Position) |
Filing History |
| 2021-01-11 09:10 am Purchase |
2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
WELLINGTON MANAGEMENT CO LLP | 3,753,364 11.230% |
3,753,364 (New Position) |
Filing History |